Ilerhunmwuwa Nosakhare Paul, Hakobyan Narek, A. Henry, Wasifuddin Mustafa, Abowali Hesham, B. Avezbakiyev
{"title":"转移性小细胞肺癌患者可能与lurbinectedin相关的心脏毒性:1例报告","authors":"Ilerhunmwuwa Nosakhare Paul, Hakobyan Narek, A. Henry, Wasifuddin Mustafa, Abowali Hesham, B. Avezbakiyev","doi":"10.29011/28333497.000152","DOIUrl":null,"url":null,"abstract":"Background: It has been a major challenge finding an effective second-line therapy with a favorable safety profile for metastatic small cell lung cancer (SCLC) in patients who failed or relapsed following first-line platinum-based chemotherapy. Lurbinectedin was approved for SCLC in patients who relapsed or failed first-line treatment. The most common adverse event associated with it was myelosuppression. Till date, no cardiotoxicity has been described with this medication in the literature.","PeriodicalId":254574,"journal":{"name":"Annals of Medical and Clinical Oncology","volume":"39 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Possible Lurbinectedin-associated Cardiotoxicity in a Patient with Metastatic Small Cell Lung Cancer: A Case Report\",\"authors\":\"Ilerhunmwuwa Nosakhare Paul, Hakobyan Narek, A. Henry, Wasifuddin Mustafa, Abowali Hesham, B. Avezbakiyev\",\"doi\":\"10.29011/28333497.000152\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: It has been a major challenge finding an effective second-line therapy with a favorable safety profile for metastatic small cell lung cancer (SCLC) in patients who failed or relapsed following first-line platinum-based chemotherapy. Lurbinectedin was approved for SCLC in patients who relapsed or failed first-line treatment. The most common adverse event associated with it was myelosuppression. Till date, no cardiotoxicity has been described with this medication in the literature.\",\"PeriodicalId\":254574,\"journal\":{\"name\":\"Annals of Medical and Clinical Oncology\",\"volume\":\"39 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-07-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Medical and Clinical Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.29011/28333497.000152\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Medical and Clinical Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29011/28333497.000152","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Possible Lurbinectedin-associated Cardiotoxicity in a Patient with Metastatic Small Cell Lung Cancer: A Case Report
Background: It has been a major challenge finding an effective second-line therapy with a favorable safety profile for metastatic small cell lung cancer (SCLC) in patients who failed or relapsed following first-line platinum-based chemotherapy. Lurbinectedin was approved for SCLC in patients who relapsed or failed first-line treatment. The most common adverse event associated with it was myelosuppression. Till date, no cardiotoxicity has been described with this medication in the literature.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
